Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EBT: 2020-2024

Historic EBT for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$84.6 million.

  • Taysha Gene Therapies' EBT fell 29.62% to -$30.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$94.1 million, marking a year-over-year decrease of 15.66%. This contributed to the annual value of -$84.6 million for FY2024, which is 14.56% down from last year.
  • Per Taysha Gene Therapies' latest filing, its EBT stood at -$84.6 million for FY2024, which was down 14.56% from -$73.9 million recorded in FY2023.
  • Taysha Gene Therapies' 5-year EBT high stood at -$43.0 million for FY2020, and its period low was -$174.5 million during FY2021.
  • Its 3-year average for EBT is -$108.2 million, with a median of -$84.6 million in 2024.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 306.05% in 2021, then spiked by 55.50% in 2023.
  • Over the past 5 years, Taysha Gene Therapies' EBT (Yearly) stood at -$43.0 million in 2020, then crashed by 306.05% to -$174.5 million in 2021, then climbed by 4.89% to -$166.0 million in 2022, then soared by 55.50% to -$73.9 million in 2023, then dropped by 14.56% to -$84.6 million in 2024.